Ebm Drugs & Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 8 Year, 4 Months
- Last Filing with ROC 31 Mar 2021
- Open Charges ₹ 2.57 Cr
About Ebm Drugs & Pharmaceuticals
Ebm Drugs & Pharmaceuticals Private Limited (EDPPL) is a Private Limited Indian Non-Government Company incorporated in India on 30 September 2016 (Eight years and four months 16 days old ). Its registered office is in Gorakhpur, Uttar Pradesh, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2021. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹2.57 Cr.
Akhilesh Singh and Rubi Singh serve as directors at the Company.
Company Details
-
Location
Gorakhpur, Uttar Pradesh, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U51909UP2016PTC086809
-
Company No.
086809
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
30 Sep 2016
-
Date of AGM
30 Nov 2021
-
Date of Balance Sheet
31 Mar 2021
-
Listing Status
Unlisted
-
ROC Code
Roc Kanpur
Industry
Who are the key members and board of directors at Ebm Drugs & Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Akhilesh Singh
|
Director | 30-Sep-2016 | Current |
|
Rubi Singh
|
Director | 30-Sep-2016 | Current |
Financial Performance of Ebm Drugs & Pharmaceuticals.
Ebm Drugs & Pharmaceuticals Private Limited, for the financial year ended 2017, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ebm Drugs & Pharmaceuticals?
In 2017, Ebm Drugs & Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹25.68 M
₹0
Charges Breakdown by Lending Institutions
- Others : 1.40 Cr
- Hdfc Bank Limited : 1.17 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 13 Sep 2024 | Hdfc Bank Limited | ₹4.37 M | Open |
| 22 May 2024 | Hdfc Bank Limited | ₹3.02 M | Open |
| 11 Dec 2023 | Others | ₹9.00 M | Open |
| 20 Sep 2021 | Hdfc Bank Limited | ₹4.30 M | Open |
| 15 Jan 2019 | Others | ₹5.00 M | Open |
How Many Employees Work at Ebm Drugs & Pharmaceuticals?
Unlock and access historical data on people associated with Ebm Drugs & Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ebm Drugs & Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ebm Drugs & Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.